Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
79 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Primary Immune Deficiency (PID) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H1 2017, provides an overview of the Primary Immune Deficiency (PID) (Genetic Disorders) pipeline landscape. Primary immunodeficiency is defined as weaken immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea and diarrhea. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 7, 1, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 3 and 3 molecules, respectively. Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) (Genetic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Primary Immune Deficiency (PID) - Overview Primary Immune Deficiency (PID) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Primary Immune Deficiency (PID) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development ADMA Biologics Inc Biotest AG Genethon SA GigaGen Inc GlaxoSmithKline Plc Green Cross Corp Novartis AG Octapharma AG ProMetic Life Sciences Inc Sangamo Therapeutics Inc Shire Plc Taiga Biotechnologies Inc UCB SA X4 Pharmaceuticals Inc Primary Immune Deficiency (PID) - Drug Profiles Antibody for Primary Immune Deficiency Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress BT-595 - Drug Profile Product Description Mechanism Of Action R&D Progress Cell Therapy for RAG-Deficient Severe Combined Immune Deficiency - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy for X-Linked SCID - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate Adenosine Deaminase for Adenosine Deaminase Deficiency Related SCID - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate IL2RG for SCID-X1 - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-2696273 - Drug Profile Product Description Mechanism Of Action R&D Progress immune globulin (human) - Drug Profile Product Description Mechanism Of Action R&D Progress immune globulin (human) - Drug Profile Product Description Mechanism Of Action R&D Progress immune globulin (human) - Drug Profile Product Description Mechanism Of Action R&D Progress immune globulin (human) 2 - Drug Profile Product Description Mechanism Of Action R&D Progress immune globulin (human) next generation - Drug Profile Product Description Mechanism Of Action R&D Progress RI-002 - Drug Profile Product Description Mechanism Of Action R&D Progress seletalisib - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit CXCL12 for Primary Immune Deficiency - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for ADA Deficiency Related SCID - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Hematological Disorders and Primary Immune Deficiency - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Leukocyte Adhesion Deficiency - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Severe Combined Immunodeficiency - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy to Activate Artemis for SCID - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy to Activate IL-2 Gamma Receptor for SCID-X1 - Drug Profile Product Description Mechanism Of Action R&D Progress TBX-1400 - Drug Profile Product Description Mechanism Of Action R&D Progress X-4P001 - Drug Profile Product Description Mechanism Of Action R&D Progress Primary Immune Deficiency (PID) - Dormant Projects Primary Immune Deficiency (PID) - Product Development Milestones Featured News & Press Releases Nov 29, 2016: Option Care Has Been Selected as a National Provider of CUVITRU Nov 23, 2016: Green Cross Receives Complete Response Letter from US FDA for IVIG-SN Nov 16, 2016: Shire Launches CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in the U.S. for Primary Immunodeficiency Nov 12, 2016: Tolerability Data for Shires Cuvitru Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual Meeting Sep 23, 2016: Shire To Showcase Data On Cuvitru During European Society For Immunodeficiencies Biennial Meeting Sep 14, 2016: Shire Announces U.S. FDA Approval of CUVITRU Treatment for Primary Immunodeficiency Aug 09, 2016: ProMetic Completes Adult Patients Enrolment in Pivotal IVIG Phase 3 Clinical Trial Jun 10, 2016: Shire announces completion of decentralized procedure in Europe for Immunoglobulin Treatment Cuvitru Mar 07, 2016: Green Cross Biotherapeutics Receives Health Canada Approval for Phase III Clinical Trials of IVIG 10% Mar 03, 2016: Baxalta to Showcase Innovation Leadership in Primary Immune Deficiencies During 2016 American Academy of Allergy, Asthma & Immunology Annual Meeting Jan 25, 2016: US FDA Accepts Green Cross' Biologics License Application for IVIG-SN Dec 02, 2015: Baxalta Receives CHMP Positive Opinion on GAMMAGARD Nov 24, 2015: Green Cross Submits Biologics License Application to US FDA for IVIG-SN Oct 26, 2015: Prometic's IVIG IND Cleared By FDA May 21, 2015: Baxter BioScience Files for European Approval of Investigational 20% Subcutaneous Immune Globulin Treatment for Primary Immunodeficiency Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Primary Immune Deficiency (PID), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics Inc, H1 2017 Primary Immune Deficiency (PID) - Pipeline by Biotest AG, H1 2017 Primary Immune Deficiency (PID) - Pipeline by Genethon SA, H1 2017 Primary Immune Deficiency (PID) - Pipeline by GigaGen Inc, H1 2017 Primary Immune Deficiency (PID) - Pipeline by GlaxoSmithKline Plc, H1 2017 Primary Immune Deficiency (PID) - Pipeline by Green Cross Corp, H1 2017 Primary Immune Deficiency (PID) - Pipeline by Novartis AG, H1 2017 Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, H1 2017 Primary Immune Deficiency (PID) - Pipeline by ProMetic Life Sciences Inc, H1 2017 Primary Immune Deficiency (PID) - Pipeline by Sangamo Therapeutics Inc, H1 2017 Primary Immune Deficiency (PID) - Pipeline by Shire Plc, H1 2017 Primary Immune Deficiency (PID) - Pipeline by Taiga Biotechnologies Inc, H1 2017 Primary Immune Deficiency (PID) - Pipeline by UCB SA, H1 2017 Primary Immune Deficiency (PID) - Pipeline by X4 Pharmaceuticals Inc, H1 2017 Primary Immune Deficiency (PID) - Dormant Projects, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
